Full results from the HAVEN 3 and 4 trials suggest that Roche’s hemophilia drug Hemlibra will indeed take a dominant market position in patients with or without factor VIII inhibitors although that make take some time as current therapy is already very effective and is supported by decades of safety experience.
Although safety concerns persist, Roche's hopes of Hemlibra (emicizumab) becoming the new standard of care for hemophilia A in both inhibitor and non-inhibitor patients have received another boost on the back of data from two closely watched studies.
The Swiss major presented full results May 21 from the HAVEN 3 and HAVEN 4 trials at the World Federation...
Also, Latest News From Europe, Canada, Saudi Arabia, Finland, China, And The US
US FDA approval of Niktimvo for third-line chronic GVHD, a competitor to Sanofi’s Rezurock, came less than two months ahead of anticipated approval of Syndax’s leukemia drug revumenib.
The company’s giroctocogene fitelparvovec, partnered with Sangamo, could compete with BioMarin’s hemophilia A gene therapy Roctavian, but longer-term data may be needed.
2seventy bio sold full rights to a hemophilia A program and in vivo gene editing technology to partner Novo Nordisk.
"Neque porro quisquam est qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit..."
Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.
Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.
![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
